• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

AbbVie to Acquire Landos Biopharma and Novel Ulcerative Colitis Investigational Drug


If the company' experimental agent is approved, it would join Humira (adalimumab), Rinvoq (upadacitinib) and Skyrizi (risankizumab) in AbbVie's portfolio.

AbbVie recently confirmed plans to acquire the clinical-stage biopharmaceutical company Lando Biopharma, headquartered in Blacksburg, Virginia. Lando focuses on developing novel oral therapies to treat autoimmune disorders, such as Crohn’s disease and ulcerative colitis. The deal is expected to conclude during the second quarter of 2024.

As part of the package, AbbVie will bring in Landos’ lead investigational agent, NX-13, a potential first-in-class oral NOD-like receptor X1 (NLRX1) agonist currently in the phase 2 NEXUS proof-of-concept study evaluating its safety and efficacy in patients with moderate to severe ulcerative colitis.

If approved, NX-13 will strengthen AbbVie’s already strong suit in inflammatory bowel disease, which includes the blockbusters Humira (adalimumab), Rinvoq (upadacitinib) and Skyrizi (risankizumab).

Roopal Thakkar, M.D.

Roopal Thakkar, M.D.

“With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-in-class, oral asset with the potential to make a difference in the lives of people living with ulcerative colitis and Crohn's disease," Roopal Thakkar, M.D., senior vice president and chief medical officer of global therapeutics at AbbVie, said in a press release.

NX-13 activates NLRX1, which regulates inflammatory proteins associated with Crohn’s disease and ulcerative colitis. Its once daily oral dosing is meant to provide a more convenient delivery method compared with current disease-modifying therapies like biologics.

The NEXUS trial is enrolling 80 participants with moderate to severe ulcerative colitis to evaluate two doses of the drug candidate. Preliminary results are anticipated toward the end of 2024.

Related Content
© 2024 MJH Life Sciences

All rights reserved.